Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA panel

Charles C J Carpenter, Margaret A Fischl, Scott M. Hammer, Martin S. Hirsch, Donna M. Jacobsen, David A. Katzenstein, Julio S G Montaner, Douglas D. Richman, Michael S. Saag, Robert T. Schooley, Melanie A. Thompson, Stefano Vella, Patrick G. Yeni, Paul A. Volberding

Research output: Contribution to journalArticle

682 Citations (Scopus)

Abstract

Objective. - To provide recommendations for antiretroviral therapy based on information available in mid-1998. Participants. - An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995. Evidence. - The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and immunologic end point data; data presented at research conferences; and studies of HIV pathophysiology); opinions of panel members were also considered. Recommendations were limited to drugs available in mid-1998. Consensus Process. - Panel members monitor new clinical research reports and interim results. The full panel meets regularly to discuss how the new information may change treatment recommendations. Updated recommendations are developed through consensus of the entire panel at each stage of development. Conclusions. - Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection. A variety of combination regimens show potency, expanding choices for initial regimens for individual patients. Plasma HIV RNA assays with increased sensitivity are important in monitoring therapeutic response; however, more data are needed to determine precisely the HIV RNA levels that define treatment failure. Long-term adverse drug effects are beginning to emerge, requiring ongoing attention. Some issues regarding optimal long-term approaches to antiretroviral management are unresolved. The increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.

Original languageEnglish
Pages (from-to)78-86
Number of pages9
JournalJournal of the American Medical Association
Volume280
Issue number1
DOIs
StatePublished - Jul 1 1998

Fingerprint

Virus Diseases
HIV
Therapeutics
RNA
Treatment Failure
Research
Pharmaceutical Preparations
Patient Care
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antiretroviral therapy for HIV infection in 1998 : Updated recommendations of the International AIDS Society-USA panel. / Carpenter, Charles C J; Fischl, Margaret A; Hammer, Scott M.; Hirsch, Martin S.; Jacobsen, Donna M.; Katzenstein, David A.; Montaner, Julio S G; Richman, Douglas D.; Saag, Michael S.; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Yeni, Patrick G.; Volberding, Paul A.

In: Journal of the American Medical Association, Vol. 280, No. 1, 01.07.1998, p. 78-86.

Research output: Contribution to journalArticle

Carpenter, CCJ, Fischl, MA, Hammer, SM, Hirsch, MS, Jacobsen, DM, Katzenstein, DA, Montaner, JSG, Richman, DD, Saag, MS, Schooley, RT, Thompson, MA, Vella, S, Yeni, PG & Volberding, PA 1998, 'Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA panel', Journal of the American Medical Association, vol. 280, no. 1, pp. 78-86. https://doi.org/10.1001/jama.280.1.78
Carpenter, Charles C J ; Fischl, Margaret A ; Hammer, Scott M. ; Hirsch, Martin S. ; Jacobsen, Donna M. ; Katzenstein, David A. ; Montaner, Julio S G ; Richman, Douglas D. ; Saag, Michael S. ; Schooley, Robert T. ; Thompson, Melanie A. ; Vella, Stefano ; Yeni, Patrick G. ; Volberding, Paul A. / Antiretroviral therapy for HIV infection in 1998 : Updated recommendations of the International AIDS Society-USA panel. In: Journal of the American Medical Association. 1998 ; Vol. 280, No. 1. pp. 78-86.
@article{745461c5c40b49938678b9237723c61b,
title = "Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA panel",
abstract = "Objective. - To provide recommendations for antiretroviral therapy based on information available in mid-1998. Participants. - An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995. Evidence. - The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and immunologic end point data; data presented at research conferences; and studies of HIV pathophysiology); opinions of panel members were also considered. Recommendations were limited to drugs available in mid-1998. Consensus Process. - Panel members monitor new clinical research reports and interim results. The full panel meets regularly to discuss how the new information may change treatment recommendations. Updated recommendations are developed through consensus of the entire panel at each stage of development. Conclusions. - Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection. A variety of combination regimens show potency, expanding choices for initial regimens for individual patients. Plasma HIV RNA assays with increased sensitivity are important in monitoring therapeutic response; however, more data are needed to determine precisely the HIV RNA levels that define treatment failure. Long-term adverse drug effects are beginning to emerge, requiring ongoing attention. Some issues regarding optimal long-term approaches to antiretroviral management are unresolved. The increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.",
author = "Carpenter, {Charles C J} and Fischl, {Margaret A} and Hammer, {Scott M.} and Hirsch, {Martin S.} and Jacobsen, {Donna M.} and Katzenstein, {David A.} and Montaner, {Julio S G} and Richman, {Douglas D.} and Saag, {Michael S.} and Schooley, {Robert T.} and Thompson, {Melanie A.} and Stefano Vella and Yeni, {Patrick G.} and Volberding, {Paul A.}",
year = "1998",
month = "7",
day = "1",
doi = "10.1001/jama.280.1.78",
language = "English",
volume = "280",
pages = "78--86",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Antiretroviral therapy for HIV infection in 1998

T2 - Updated recommendations of the International AIDS Society-USA panel

AU - Carpenter, Charles C J

AU - Fischl, Margaret A

AU - Hammer, Scott M.

AU - Hirsch, Martin S.

AU - Jacobsen, Donna M.

AU - Katzenstein, David A.

AU - Montaner, Julio S G

AU - Richman, Douglas D.

AU - Saag, Michael S.

AU - Schooley, Robert T.

AU - Thompson, Melanie A.

AU - Vella, Stefano

AU - Yeni, Patrick G.

AU - Volberding, Paul A.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Objective. - To provide recommendations for antiretroviral therapy based on information available in mid-1998. Participants. - An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995. Evidence. - The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and immunologic end point data; data presented at research conferences; and studies of HIV pathophysiology); opinions of panel members were also considered. Recommendations were limited to drugs available in mid-1998. Consensus Process. - Panel members monitor new clinical research reports and interim results. The full panel meets regularly to discuss how the new information may change treatment recommendations. Updated recommendations are developed through consensus of the entire panel at each stage of development. Conclusions. - Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection. A variety of combination regimens show potency, expanding choices for initial regimens for individual patients. Plasma HIV RNA assays with increased sensitivity are important in monitoring therapeutic response; however, more data are needed to determine precisely the HIV RNA levels that define treatment failure. Long-term adverse drug effects are beginning to emerge, requiring ongoing attention. Some issues regarding optimal long-term approaches to antiretroviral management are unresolved. The increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.

AB - Objective. - To provide recommendations for antiretroviral therapy based on information available in mid-1998. Participants. - An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995. Evidence. - The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and immunologic end point data; data presented at research conferences; and studies of HIV pathophysiology); opinions of panel members were also considered. Recommendations were limited to drugs available in mid-1998. Consensus Process. - Panel members monitor new clinical research reports and interim results. The full panel meets regularly to discuss how the new information may change treatment recommendations. Updated recommendations are developed through consensus of the entire panel at each stage of development. Conclusions. - Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection. A variety of combination regimens show potency, expanding choices for initial regimens for individual patients. Plasma HIV RNA assays with increased sensitivity are important in monitoring therapeutic response; however, more data are needed to determine precisely the HIV RNA levels that define treatment failure. Long-term adverse drug effects are beginning to emerge, requiring ongoing attention. Some issues regarding optimal long-term approaches to antiretroviral management are unresolved. The increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0007010412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0007010412&partnerID=8YFLogxK

U2 - 10.1001/jama.280.1.78

DO - 10.1001/jama.280.1.78

M3 - Article

C2 - 9660368

AN - SCOPUS:0007010412

VL - 280

SP - 78

EP - 86

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 1

ER -